Brought to you by 
Schering AG licenses more rights to Ilex's Campath; ends
08 Apr 2009
Executive Summary
Expanding their 1999 deal, Ilex Oncology (anticancer drugs) licensed Schering AG exclusive development and marketing rights in Japan, China, and the Asian Pacific Basin (areas that were excluded in the original agreement) to Campath (alemtuzumab), a monoclonal antibody against the CD52 antigen. Schering now has exclusive worldwide rights to the drug.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Concluded
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schering AG licenses more rights to Ilex's Campath; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice